Addex Therapeutics Ltd has experienced a significant 95.77% decline in stock value over the past five years, from 1.39 CHF to 0.0588 CHF, amidst broader market fluctuations and sector-specific challenges.

Addex Therapeutics Ltd is making significant strides in developing treatments for chronic cough, with promising preclinical data and upcoming presentations at key conferences.

Addex Therapeutics navigated a challenging financial year with strategic advancements in neurological disorders, including a successful Series A funding round and partnerships, despite a decline in stock value.